Tango Therapeutics, Inc. - Common Stock TNGX 深 滬
交易中 09-19 12:25:53 美东时间
8.43
+0.150
+1.81%
華盛通- 最 高8.67
- 今 開8.51
- 成交量 25.72万股
- 最 低 8.34
- 昨 收 8.28
- 總市值 8.60亿
- 52周最高 13.03
- 市盈率 靜 --
- 換手率 0.25%
- 52周最低 5.15
- 委 比 -88.38%
- 總股本 1.02亿
- 歷史最高 18.84
- 量 比 0.40
- 振 幅 3.99%
- 歷史最低 2.47
- 每 手 1
- 風險率 1.63%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Cantor sees Tango benefitting from Ideaya's positive data
Cantor Fitzgerald said it sees Tango Therapeutics (NASDAQ:TNGX) benefitting from Ideaya’s (IDYA) positive Phase 2 data for its MAT2A inhibitor IDE397 in the treatment of non-small cell lung and urothe...
07-10 01:42
Guggenheim：维持Tango Therapeutics(TNGX.US)评级，由买入调整至买入评级, 目标价由16.00美元调整至14.00美元。
Guggenheim：维持Tango Therapeutics(TNGX.US)评级，由买入调整至买入评级, 目标价由16.00美元调整至14.00美元。
05-25 00:31
Forecasting The Future: 4 Analyst Projections For Tango Therapeutics
Analysts' ratings for Tango Therapeutics (NASDAQ:TNGX) over the last quarter va...
05-24 23:01
Tango Therapeutics Shuts Early-Stage Cancer Study Due To Liver Toxicity
Tango Therapeutics halts its TNG348 program due to liver toxicity issues found in dose escalation studies. The company will now focus on its PRMT5 program and plans to update on TNG908 and TNG462 later this year.
05-24 00:53
Wedbush Maintains Outperform on Tango Therapeutics, Lowers Price Target to $11
Wedbush analyst Robert Driscoll maintains Tango Therapeutics (NASDAQ:TNGX) with a Outperform and lowers the price target from $18 to $11.
05-24 00:35
Medivir ́s Licensee, Tango Therapeutics, Has Discontinued Development of Its TNG348 Clinical Program
STOCKHOLM, May 23, 2024 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a ...
05-23 21:18
DQ, BNED and BDRX among pre-market losers
Losers: Barnes & Noble Education (BNED) -38%. MGO Global (MGOL) -29%. Cytokinetics (CYTK) -15% announces proposed offering of shares. VF Corp. (VFC) -13% after Q4 earnings release. Tango Therapeutics ...
05-23 20:24
Tango Therapeutics to discontinue development of TNG348 program
Tango Therapeutics (NASDAQ:TNGX) said it will discontinue development of its TNG348 program. No patient had yet received a combination of TNG348 and olaparib, the company. More on Tango Therapeutics S...
05-23 19:17
Tango Therapeutics Q1 GAAP EPS of -$0.35 misses by $0.04
Tango Therapeutics press release (NASDAQ:TNGX): Q1 GAAP EPS of -$0.35 misses by $0.04. Q1 collaboration revenue was $6.5 million, compared to $5.8 million for the same period in 2023. Reports strong c...
05-08 21:52
Tango Therapeutics, Inc.'s (NASDAQ:TNGX) Shareholders Might Be Looking For Exit
Tango Therapeutics, Inc.'s (NASDAQ:TNGX) price-to-sales (or "P/S") ratio of 23x...
04-30 18:51
